Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 91,714 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $19.26, for a total value of $1,766,411.64. Following the completion of the sale, the chief executive officer now directly owns 152,504 shares of the company’s stock, valued at $2,937,227.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Nektar Therapeutics (NASDAQ:NKTR) opened at 18.04 on Friday. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $24.88. The company’s market capitalization is $2.82 billion. The stock has a 50 day moving average price of $20.49 and a 200-day moving average price of $18.57.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.04. The company had revenue of $34.60 million during the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.36) earnings per share. Equities analysts predict that Nektar Therapeutics will post ($0.94) EPS for the current fiscal year.

WARNING: “Howard W. Robin Sells 91,714 Shares of Nektar Therapeutics (NKTR) Stock” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/howard-w-robin-sells-91714-shares-of-nektar-therapeutics-nktr-stock/1509720.html.

NKTR has been the subject of a number of recent research reports. Roth Capital set a $31.00 target price on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Monday, May 22nd. Jefferies Group LLC decreased their target price on Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, May 10th. Aegis reissued a “buy” rating and issued a $27.00 target price on shares of Nektar Therapeutics in a research report on Wednesday, May 10th. BidaskClub raised Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Tuesday, August 1st. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $26.10.

Several large investors have recently bought and sold shares of NKTR. Flinton Capital Management LLC raised its stake in Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 692 shares during the period. Meadow Creek Investment Management LLC raised its stake in Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 616 shares during the period. LS Investment Advisors LLC raised its stake in Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares during the period. Finally, Glen Harbor Capital Management LLC raised its stake in Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 784 shares during the period. Hedge funds and other institutional investors own 93.02% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.